Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Calithera Biosciences Inc. ($CALA) announced that it is now eligible to claim a $12 million milestone payment from its collaboration partner Incyte. The milestone payment has been triggered by the achievement of pharmacokinetic and pharmacodynamic goals for oncology candidate CB-1158. Both the companies had entered into a global collaboration and license agreement for the research, development and commercialization of  CB-1158 in hematology and oncology in January this year.

CB-1158 is currently being studied in a monotherapy dose escalation clinical trial and also in combination with anti-PD-1 therapy.   Additional studies are also expected to be conducted. Calithera stock gained over 5 percent in the pre-market session. It has gained over 103 percent in the past 12 months.

Exact Sciences Corporation ($EXAS) stock jumped over 9 percent in its Monday trading session on the news that the company’s Cologuard has been added by Aetna to its list of covered tests for colorectal cancer screening. This will add commercial coverage to the previously announced Medicare Advantage inclusion. Cologuard is the first FDA approved stool-based DNA screening test for colon cancer.

The company stock has shown strong performance as it soared above 273 percent in the past 12 months. This year so far, Exact Sciences stock is up 72 percent. Stock analysis firm Cowen has given Outperform rating to the stock and its price target has been set at $30.


Ziopharm Oncology ($ZIOP) reported that  it has received FDA guidance from an End-of-Phase 2 meeting regarding lead gene therapy candidate Ad-RTS-hIL-12 for treating an aggressive type of brain cancer called recurrent glioblastoma. The drug candidate is being tested in combination with orally administered veledimex. Ziopharm plans to advance the gene therapy, which utilizes its RheoSwitch platform, into Phase 3 development this year.

Foamix Pharmaceuticals ($FOMX) announced mixed results from two Phase 3 clinical trials assessing FMX101 in people with moderate-to-severe acne. Its Trial 04 met only one co-primary endpoints while Trial 05 met both. Specifically, both studies showed treatment with FMX101 produced statistically significant reductions in the number of inflammatory lesions versus baseline compared to placebo.

Innovus Pharmaceuticals ($INNV) reported receiving a Notice of Intention to Grant from the European Patent Office for a patent titled "Sensitization composition and method of use" covering its Sensum + product for reduced penile sensitivity. The company CEO Dr. Bassam Damaj said that the receipt of Notice of Intention to Grant from the EPO adds great value to the CPNP notification we received earlier in the month to market Sensum+® in Europe.

Pfizer ($PFE) announced that it has received the approval from the European Commission for XELJANZ (tofacitinib citrate) 5 mg twice daily, in combination with methotrexate, for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who failed to respond adequately to or who are intolerant of one or more disease-modifying antirheumatic drugs. The advisory committee CHMP adopted a positive opinion backing approval in January.


Integra LifeSciences ($IART) entered into an exclusive deal with Dr. Reddy's Laboratories for the marketing and distribution of DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices in India. The DuraGen product line offers Duraplasty Solutions and DuraGen Plus Dural Regeneration Matrix.

Roche ($RHHBY) announced that it has launched  its cobas HPV cervical cancer screening test on its automated cobas 6800/8800 Systems in countries that recognize the CE mark. The automated 6800/8800 lab systems generate up to 96 results in less than 3.5 hours. A clinical study called ATHENA showed screening strategies using cobas HPV detected more high-grade disease than Pap testing alone.


Aradigm Corporation ($ARDM) announced that it recorded $125,000 in revenue in the fourth quarter of 2016 compared with $35,000 in revenue in the fourth quarter of 2015. Its net loss for the fourth quarter of 2016 was $7.9 million, or $0.54 per share, compared with a net loss of $9.4 million, or $0.63 per share, for the same period in 2015. Aradigm’s revenue for the year ended December 31, 2016 were $195,000, compared with revenues of $23.4 million in 2015, while its net loss for the year ended December 31, 2016 was $32.9 million, or $2.23 per share.

Reliv International Inc. ($RLV) reported that it earned net income of $272,000, or earnings of $0.15 per diluted share, for the fourth quarter of 2016 compared with a net loss of $206,000, or a loss of $0.11 per diluted share for the corresponding period of the previous year. The company reported its net sales at $10.6 million, down from $12.3 million it had reported for the fourth quarter of 2015.

Price Target
Impact on Share Price
Deutsche Bank AG
Raises Target
Allergan plc (AGN)

HC Wainwright
Calithera Biosciences (CALA)
Buy -> Buy
$10.00 -> $14.00
HC Wainwright
Raises Target
Cara Therapeutics (CARA)
$22.00 -> $30.00
Cowen and Company
Edwards Lifesciences Corp (EW)
Credit Suisse Group AG
Lowers Target
Foamix Pharmaceuticals Ltd (FOMX)

Matinas BioPharma Holdings (MTNB)
Buy -> Positive
Novocure Ltd (NVCR)

Bank of America Corp
Premier (PINC)
Underperform -> Buy
Robert W. Baird
Regeneron Pharmaceuticals (REGN)
Piper Jaffray Companies
Reata Pharmaceuticals (RETA)
Needham & Company LLC
Selecta Biosciences (SELB)

Gainers (% price change)Last TradeChangeMkt CapImpax Laboratories IncIPXL12.70+3.45 (37.30%)941.69MCatalyst PharmaceuticalsCPRX2.01+0.31 (18.24%)168.76MZIOPHARM Oncology Inc.ZIOP6.69+0.81 (13.78%)887.11MNova MeasuringNVMI18.77+1.96 (11.66%)508.94MOmeros CorporationOMER12.67+1.11 (9.60%)565.00MLosers (% price change)Progenics PharmaceuticalsPGNX10.84-0.42 (-3.73%)772.52MCryolife IncCRY16.55-0.60 (-3.50%)560.54MClovis Oncology IncCLVS68.31-2.01 (-2.86%)3.13BCuris, Inc.CRIS2.88-0.08 (-2.70%)422.93MBIO-TECHNE CorpTECH101.02-2.80 (-2.70%)3.78BMost Actives (dollar volume)Amgen, Inc.AMGN164.91-0.83 (-0.50%)121.23BHCA Holdings IncHCA90.49+4.45 (5.17%)34.68BUnitedHealth Group IncUNH164.60-0.40 (-0.24%)156.29BJohnson & JohnsonJNJ125.80+0.32 (0.26%)339.89BBristol-Myers Squibb CoBMY56.04+0.15 (0.27%)92.52B